These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 28626533)

  • 1. Synthesis and Anti-HCV Activity of a Novel 2',3'-Dideoxy-2'-α-fluoro-2'-β-
    Yu W; Li E; Lv Z; Liu K; Guo X; Liu Y; Chang J
    ACS Med Chem Lett; 2017 Jun; 8(6):682-684. PubMed ID: 28626533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of a novel β-D-2'-deoxy-2'-α-fluoro-2'-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection.
    Li E; Wang Y; Yu W; Lv Z; Peng Y; Liu B; Li S; Ho W; Wang Q; Li H; Chang J
    Eur J Med Chem; 2018 Jan; 143():107-113. PubMed ID: 29172078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.
    Vernachio JH; Bleiman B; Bryant KD; Chamberlain S; Hunley D; Hutchins J; Ames B; Gorovits E; Ganguly B; Hall A; Kolykhalov A; Liu Y; Muhammad J; Raja N; Walters CR; Wang J; Williams K; Patti JM; Henson G; Madela K; Aljarah M; Gilles A; McGuigan C
    Antimicrob Agents Chemother; 2011 May; 55(5):1843-51. PubMed ID: 21357300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
    Good SS; Moussa A; Zhou XJ; Pietropaolo K; Sommadossi JP
    PLoS One; 2020; 15(1):e0227104. PubMed ID: 31914458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.
    Stuyver LJ; McBrayer TR; Tharnish PM; Clark J; Hollecker L; Lostia S; Nachman T; Grier J; Bennett MA; Xie MY; Schinazi RF; Morrey JD; Julander JL; Furman PA; Otto MJ
    Antivir Chem Chemother; 2006; 17(2):79-87. PubMed ID: 17042329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor.
    Sizun G; Pierra C; Peyronnet J; Badaroux E; Rabeson C; Benzaria-Prad S; Surleraux D; Loi AG; Musiu C; Liuzzi M; Seifer M; Standring D; Sommadossi JP; Gosselin G
    Future Med Chem; 2015; 7(13):1675-700. PubMed ID: 26424162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection.
    Chang W; Bao D; Chun BK; Naduthambi D; Nagarathnam D; Rachakonda S; Reddy PG; Ross BS; Zhang HR; Bansal S; Espiritu CL; Keilman M; Lam AM; Niu C; Steuer HM; Furman PA; Otto MJ; Sofia MJ
    ACS Med Chem Lett; 2011 Feb; 2(2):130-5. PubMed ID: 24900291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
    Le Pogam S; Jiang WR; Leveque V; Rajyaguru S; Ma H; Kang H; Jiang S; Singer M; Ali S; Klumpp K; Smith D; Symons J; Cammack N; Nájera I
    Virology; 2006 Aug; 351(2):349-59. PubMed ID: 16713611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents.
    Guo S; Xu M; Guo Q; Zhu F; Jiang X; Xie Y; Shen J
    Bioorg Med Chem; 2019 Mar; 27(5):748-759. PubMed ID: 30683552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
    Kirschberg TA; Mish MR; Zhang L; Squires NH; Wang KY; Cho A; Feng JY; Fenaux M; Babusis D; Park Y; Ray AS; Kim CU
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1040-3. PubMed ID: 25650256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
    Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
    Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects.
    Han B; Martin R; Xu S; Parvangada A; Svarovskaia ES; Mo H; Dvory-Sobol H
    Antiviral Res; 2019 Oct; 170():104574. PubMed ID: 31394118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 2,3-dideoxy-2-fluoro-2,3-endo-methylene- and 2,3-Dideoxy-2-fluoro-3-C-hydroxymethyl-2,3-endo-methylene-pentofuranoses and their use in the preparation of conformationally locked bicyclic nucleosides.
    Clarkson R; Komsta Z; Mayes BA; Moussa A; Shelbourne M; Stewart A; Tyrrell AJ; Wallis LL; Weymouth-Wilson AC
    J Org Chem; 2015 Feb; 80(4):2198-215. PubMed ID: 25615008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitro.
    Tyndall EM; Draffan AG; Frey B; Pool B; Halim R; Jahangiri S; Bond S; Wirth V; Luttick A; Tilmanis D; Thomas J; Porter K; Tucker SP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):869-73. PubMed ID: 25592710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 2'-spirocyclic ethers in HCV nucleoside design.
    Du J; Chun BK; Mosley RT; Bansal S; Bao H; Espiritu C; Lam AM; Murakami E; Niu C; Micolochick Steuer HM; Furman PA; Sofia MJ
    J Med Chem; 2014 Mar; 57(5):1826-35. PubMed ID: 24079820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication.
    Zhou L; Zhang H; Tao S; Ehteshami M; Cho JH; McBrayer TR; Tharnish P; Whitaker T; Amblard F; Coats SJ; Schinazi RF
    ACS Med Chem Lett; 2016 Jan; 7(1):17-22. PubMed ID: 26819659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.
    Kaushik-Basu N; Ratmanova NK; Manvar D; Belov DS; Cevik O; Basu A; Yerukhimovich MM; Lukyanenko ER; Andreev IA; Belov GM; Manfroni G; Cecchetti V; Frick DN; Kurkin AV; Altieri A; Barreca ML
    Eur J Med Chem; 2016 Oct; 122():319-325. PubMed ID: 27376494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
    Yang H; Yang C; Wang Y; Rhodes G; Robinson M; Cheng G; Qi X; Mo H; Tian Y; Pakdaman R; Sheng XC; Kim CU; Delaney WE
    Antivir Ther; 2017; 22(5):413-420. PubMed ID: 28106531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.